Generalized Pustular Psoriasis Flare-Up after Both Doses of BBIBP-CorV Vaccination in a Patient under Adalimumab Treatment: A Case Report

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Generalized pustular psoriasis is a possibly serious condition that can be triggered by various factors. Previous studies show a slight likelihood of disease exacerbation subsequent to COVID-19 vaccination. Here, we present the first (to the best of our knowledge) case of pustular psoriasis flare after each one of the two shots of the BBIBP-CorV (Sinopharm) vaccine despite adalimumab treatment.

Related collections

Most cited references 15

Record: found
Abstract: found
Article: not found

Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2

Hui WANG, Yuntao Zhang, Baoying Huang … (2020)

Summary The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.

0 comments Cited 438 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Robert Kalb, David Fiorentino, Mark G. Lebwohl … (2015)

The efficacy of treatment for psoriasis must be balanced against potential adverse events.

0 comments Cited 75 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

COVID-19 vaccine safety and efficacy in patients with Immune-Mediated Inflammatory Disease: Review of available evidence

Sarah Wack, Timothy Patton, Laura K. Ferris (2021)

Dermatologists diagnose and treat many immune-mediated inflammatory diseases (IMID). Understanding the inherent immune dysregulation of these diseases as well as the additional disruption that comes as a result of IMID treatments has been important during the COVID-19 pandemic. With vaccines becoming widely available, dermatologists need to be familiar with the risks and benefits of vaccination in these patients, particularly those taking biologics, in order to have informed discussions with their patients. In this review, we present the current evidence related to COVID-19 vaccine safety and efficacy in patients with IMID and review existing recommendations for vaccination against SARS-CoV-2. Given the current evidence, there is minimal concern that these patients are at any greater risk of harm from COVID-19 vaccination compared to healthy controls. For most, the benefit of avoiding severe COVID-19 through vaccination will outweigh the theoretical risk of these vaccines. An outstanding question is whether patients on biologics will generate a sufficient immune response to the vaccine, which may be dependent on the specific biologic therapy and indication being treated. This underscores the importance of following patients with IMID after vaccination to determine vaccine safety, efficacy, and duration in this population.

0 comments Cited 59 times – based on 0 reviews      Review now

All references

Author and article information

Journal

Journal ID (nlm-ta): Case Rep Dermatol

Journal ID (iso-abbrev): Case Rep Dermatol

Journal ID (hwp): CDE

Journal ID (publisher-id): CDE

Title: Case Reports in Dermatology

Publisher: S. Karger AG (Basel, Switzerland )

ISSN (Electronic): 1662-6567

Publication date (Electronic): 19 April 2023

Publication date Collection: Jan-Dec 2023

Publication date PMC-release: 19 April 2023

Volume: 15

Issue: 1

Pages: 61-65

Affiliations

[a ]School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

[b ]Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

[c ]Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

Author notes

Correspondence to: Kamran Balighi, Balighik@ 123456sina.tums.ac.ir

Article

Publisher ID: 530074

DOI: 10.1159/000530074

PMC ID: 10116389

PubMed ID: 37089907

SO-VID: eeb4b0b1-558b-4be4-b12b-139924c06f40

License:

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

History

Date received : 12 October 2022

Date accepted : 15 February 2023

Date: 2023

Page count

Figures: 3, References: 15, Pages: 5

Funding

No funding was received for this study.

Comments

Comment on this article

Cited by 3

See all cited by

Most referenced authors 160

See all reference authors

- Version 1
- Version 1

Call for Papers: Skin Health in Aging Populations

Submit here by August 31, 2025